Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, has announced the granting of stock options to three new employees. These options allow the purchase of 118,800 shares of the company's common stock, effective October 1, 2024. The grants were approved by the Compensation Committee and issued under Olema's 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The stock options have a 10-year term and an exercise price of $12.30 per share, matching the last reported sale price on October 1, 2024. They vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, subject to continuous employment. This announcement is made in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals, un'azienda biotecnologica in fase clinica focalizzata su terapie mirate per i tumori femminili, ha annunciato l'assegnazione di opzioni sul capitale a tre nuovi dipendenti. Queste opzioni consentono l'acquisto di 118.800 azioni delle azioni ordinarie dell'azienda, con effetto dal 1 ottobre 2024. Le concessioni sono state approvate dal Comitato Compensi e rilasciate nell'ambito del Piano di Incentivo 2022 di Olema, in conformità alla Normativa di Quotazione Nasdaq 5635(c)(4).
Le opzioni azionarie hanno un termine di 10 anni e un prezzo di esercizio di 12,30 dollari per azione, corrispondente all'ultimo prezzo di vendita riportato il 1 ottobre 2024. Si maturano nell'arco di quattro anni, con il 25% che matura al primo anniversario e il resto in 36 rate mensili uguali, soggette a un impiego continuativo. Questo annuncio è fatto in conformità con la Normativa di Quotazione Nasdaq 5635(c)(4).
Olema Pharmaceuticals, una empresa biofarmacéutica en etapa clínica centrada en terapias dirigidas para el cáncer femenino, ha anunciado la concesión de opciones sobre acciones a tres nuevos empleados. Estas opciones permiten la compra de 118,800 acciones de la acción ordinaria de la empresa, con efecto a partir del 1 de octubre de 2024. Las concesiones fueron aprobadas por el Comité de Compensación y emitidas bajo el Plan de Incentivo 2022 de Olema, de conformidad con la Regla de Cotización Nasdaq 5635(c)(4).
Las opciones sobre acciones tienen un plazo de 10 años y un precio de ejercicio de $12.30 por acción, igualando el último precio de venta informado el 1 de octubre de 2024. Se consolidan durante cuatro años, con un 25% consolidándose en el primer aniversario y el restante en 36 cuotas mensuales iguales, sujeto a empleo continuo. Este anuncio se realiza de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
여성 암을 위한 표적 치료에 집중하는 임상 단계의 생명공학 회사인 올레마 제약이 세 명의 신입 직원에게 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 2024년 10월 1일부터 118,800주의 회사 보통주를 구매할 수 있도록 합니다. 이 부여는 보상 위원회의 승인을 받았으며, 올레마의 2022년 유인 계획에 따라 발급되었습니다. 이는 나스닥 상장 규칙 5635(c)(4)에 따라 진행되었습니다.
주식 옵션은 10년의 유효 기간과 주당 $12.30의 행사 가격을 가지며, 2024년 10월 1일에 보고된 마지막 판매 가격과 일치합니다. 이 옵션은 4년에 걸쳐 분할 지급되며, 첫 해의 기념일에 25%가 취득되고 나머지는 36개월 동안 동일한 월 할부로 지급되며, 지속적인 고용이 조건입니다. 이 발표는 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Olema Pharmaceuticals, une entreprise biopharmaceutique en phase clinique axée sur les thérapies ciblées pour les cancers féminins, a annoncé l'octroi d'options d'achat d'actions à trois nouveaux employés. Ces options permettent l'achat de 118 800 actions des actions ordinaires de l'entreprise, à compter du 1er octobre 2024. Les attributions ont été approuvées par le Comité de Rémunération et émises dans le cadre du Plan d'Incitation 2022 d'Olema, conformément à la Règle d'Inscription Nasdaq 5635(c)(4).
Les options d'achat d'actions ont une durée de 10 ans et un prix d'exercice de 12,30 $ par action, correspondant au dernier prix de vente rapporté le 1er octobre 2024. Elles se concrétisent sur quatre ans, avec 25 % devant se concrétiser lors du premier anniversaire et le reste en 36 versements mensuels égaux, soumis à un emploi continu. Cette annonce est faite conformément à la Règle d'Inscription Nasdaq 5635(c)(4).
Olema Pharmaceuticals, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien für Frauenkrebserkrankungen konzentriert, hat die Gewährung von Aktienoptionen an drei neue Mitarbeiter bekannt gegeben. Diese Optionen ermöglichen den Kauf von 118.800 Aktien der Stammaktien des Unternehmens, mit Wirkung zum 1. Oktober 2024. Die Gewährungen wurden vom Vergütungsausschuss genehmigt und im Rahmen von Olemas 2022 Incentive-Plan ausgegeben, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von 12,30 $ pro Aktie, der dem zuletzt am 1. Oktober 2024 gemeldeten Verkaufspreis entspricht. Sie fallen über vier Jahre an, wobei 25 % am ersten Jahrestag und der Rest in 36 gleichen monatlichen Raten anfallen, abhängig von einer fortgesetzten Beschäftigung. Diese Mitteilung erfolgt gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Olema Oncology is attracting new talent with stock option incentives
- The company is complying with Nasdaq listing rules, demonstrating good corporate governance
- Potential dilution of existing shareholders' equity due to new stock options
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 118,800 shares of the Company's common stock, effective as of October 1, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of October 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Investor Relations and Communications
ir@olema.com
FAQ
How many new employees received stock options from Olema Oncology (OLMA) on October 1, 2024?
What is the total number of shares covered by the stock options granted by Olema Pharmaceuticals (OLMA) on October 1, 2024?
What is the exercise price of the stock options granted by Olema Oncology (OLMA) on October 1, 2024?
What is the vesting schedule for the stock options granted by Olema Pharmaceuticals (OLMA) on October 1, 2024?
